1016234-87-9Relevant articles and documents
Crystal structure and catalytic properties of a vanadium complex cis-[VO2(Him-py)(im-py)]2·3H2O
Sun, Meng,Zhang, Shaowei,Zhang, Jie,Xia, Wen,Chen, Jialiang,Yu, Xianyong
, p. 1899 - 1909 (2019)
The coordination behavior of Him-py (2-(1H-imidazol-2-yl)pyridine) toward vanadium has been explored. The six-coordinate complex, cis-[VO2(Him-py)(im-py)]2·3H2O (1), was synthesized by the coordination reaction of NH4VO3 and Him-py in the aqueous methanol solution, which was characterized by single-crystal X-ray technology. It belongs to the monoclinic space group P21/n with a = 8.0756(6), b = 19.3531(15), c = 11.4433(8), β = 106.905(2), V = 1711.2(2), and Z = 2. The crystal structure shows that the six-coordinate vanadium is bonded to two cis-oxido ligands and two bidentate ligands, Him-py and im-py. Interestingly, when crystals of 1 were immersed in H2O2, a peroxovanadium compound, (H2im-py)[OV(O2)2(Him-py)] (2), was obtained, which crystallizes in the orthorhombic space group Fdd2 with a = 22.600(2), b = 22.7259(13), c = 18.0146(11), V = 9252.4(12), and Z = 16, and consists of a seven-coordinate peroxovanadate(V) ion, one Him-py and one H2im-py ligand. Moreover, we also studied the catalytic activity of 1 in the oxidative bromination of phenol/aniline-like compounds towards mimicking bromoperoxidase reactivity.
Crystal structure, NMR and catalytic properties of a bis-peroxovanadium [NH4][VO(O2)2(mpa)]·H2O
Chen, Ping,Zhang, Shaowei,Zhang, Jie,Xia, Wen,Yu, Xianyong
, p. 239 - 250 (2019)
By reacting NH4VO3 and mpa (mpa = 4-methoxypicolinamide) in the presence of H2O2, a bis-peroxovanadium [NH4][VO(O2)2(mpa)]·H2O (1) was obtained and characterized by X-ray single-crystal diffraction. Structural analyses demonstrate that 1 belongs to the monoclinic space group P21/c and consists of a bis-peroxovanadium [VO(O2)2(mpa)]?, one NH4+ counterion and one free lattice water. Adjacent [VO(O2)2(mpa)]? anions construct a 3D supramolecular framework through intra- and intermolecular hydrogen bonding interactions. The compositions of 1 in solution are investigated by using multinuclear (1H, 13C, and 51V) magnetic resonance, COSY, HSQC, HMBC, and variable temperature NMR in a 0.15 mol L?1 NaCl/D2O solution that mimics the physiological conditions. Comparing the results of single-crystal X-ray and NMR experiments, the VV ion in the undissociated [VO(O2)2(mpa)]? in solution displays a similar seven-coordinate distorted pentagonal bipyramidal geometry with the solid-state crystal. The catalytic activity of the 1 in the oxidative bromination for phenol/aniline-like compounds to mimic bromoperoxidases reactivity was also studied.
NOVEL PROTEIN KINASE INHIBITORS
-
Page/Page column 62-63, (2021/10/30)
The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, conditions, or disorders, which respond to the inhibition of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) activity, or a combination thereof, are also described.
Novel pyrimidine derivative showing growth inhibition of cancer cell and pharmaceutical composition comprising the same
-
Paragraph 0124; 0127; 0139-0140, (2020/12/05)
The present invention provides a novel compound represented by chemical formula 1 or a salt thereof, and a pharmaceutical composition for treating lung cancer containing the same. Since the pyrimidine derivative compound represented by the chemical formul
ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF
-
Paragraph 0368, (2020/01/02)
The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE
-
Paragraph 000434, (2015/11/27)
The invention provides tetrahydroquinoline sulfonamide compounds, tetrahydronaphthalene sulfonyl compounds, and related compounds, pharmaceutical compositions, methods of promoting RORy activity, methods of increasing the amount of IL-17 in a subject, and methods of treating cancer and other medical disorders using such compounds.
BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS
-
Page/Page column 65-66, (2010/12/17)
The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical comp
New progesterone receptor modulators
-
Page/Page column 6-7, (2010/11/30)
The present invention provides new progesterone receptor modulators which are (cis)-8-fluorodibenzo[b,f]pyrido[1,2-d]oxazepine-1-amine compounds and uses thereof.
PYRIDOOXAZEPINE PROGESTERON RECEPTOR MODULATORS
-
Page/Page column 15, (2008/06/13)
The present invention provides new progesterone receptor modulators (I) and (II) which are (cis)-8-fluorodibenzo[b,f]pyrido[1,2-d] oxazepine-1 -amine compounds and uses thereof.